Saroglitazar has been shown to act as a PPAR-α/γ agonist, decreasing liver fat content and alanine transaminase (ALT) in NAFLD/NASH patients (NCT03061721).107. This evidence concerns the gene PPARA and metabolic dysfunction-associated steatohepatitis.